Perspectives

Diabetes-associated cognitive dysfunction

Highlights from CTAD 2022

Photobiomodulation: why target the brain and the gut?

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

Ongoing and future efforts in functional genomics in Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

The future of SAGE-718 in Alzheimer’s disease treatment

Ageism in the healthcare system

Progress in the Davos Alzheimer’s Collaborative’s Global Cohort Development program

The Davos Alzheimer’s Collaborative

Using digital technology to build a truly global cohort in Alzheimer’s disease

Considering non-cognitive markers in dementia

Guiding patients on intermittent fasting for brain health